ED (Erectile Dysfunction)
BDNF-hypersecreting human umbilical cord blood mesenchymal stem cells promote erectile function in a rat model of cavernous nerve electrocautery injury
Erectile dysfunction (ED) continues to be a significant problem for men following radical prostatectomy. This study concluded that intracavernous injection of BDNF-hypersecreting human umbilical cord mesenchymal stem cells (hUCB-MSCs) can enhance the recovery of erectile function, promote the cavernous nerves regeneration and inhibit corpus cavernosum fibrosis after cavernous nerve electrocautery injury in a rat model.
Erectile dysfunction treated with intracavernous stem cells: A promising new therapy?
In the past decades, great interest has been shown in the development of new therapies for erectile dysfunction. Stem cell therapy has generated promising results in numerous preclinical trials in animal models, which is why it has led to the development of the first clinical trials in humans.
Stem-cell therapy for erectile dysfunction
Erectile dysfunction (ED) is the most common sexual disorder that men report to healthcare providers, and is the male sexual dysfunction that has been most investigated. Current treatments for ED focus on relieving the symptoms of ED and therefore tend to provide a temporary solution or reversing the cause.
Stem Cell Therapy for Erectile Dysfunction: Progress and Future Directions
Currently, the treatment of ED focuses on symptomatic relief of ED and therefore tends to provide temporary relief or reversing the underlying cause. Recently, stem cell-based therapies have received increasing attention regarding their potential for the recovery of erectile function. Preclinical studies have shown that these cells may reverse pathophysiological changes leading to ED rather than treating the symptom ED.
Multipotent stromal cell therapy for cavernous nerve injury-induced erectile dysfunction
Erectile dysfunction (ED) following radical prostatectomy (RP) is a result of inadvertent damage to the cavernous nerves that run close to the prostate capsula. Multipotent stromal cells (MSCs) are an attractive cell source for this application based on their potential and their clinical applicability. MSCs from both bone marrow and adipose tissue have shown beneficial effects in a variety of animal models for ED. While the type of model may influence the mechanisms of action of this MSC-based therapy, MSCs generally display efficacy in various animal models for ED.
Stem cell therapies in post-prostatectomy erectile dysfunction: a critical review
Erectile dysfunction (ED) is still a common complication of radical prostatectomy. Current treatments of ED are mainly symptomatic. Mesenchymal stem cells (MSCs) have been widely investigated as a potential curative treatment. MSC therapy consistently improved erectile functions after cavernous nerve injury (CNI). There seems to be a consensus on the disease model used and outcome evaluation however further studies should be done.
Advances in stem cell research for the treatment of male sexual dysfunctions
This review summarizes recent literature on basic stem cell research in erectile dysfunction in cavernous nerve injury, aging, diabetes, and Peyronie’s disease and to provide a perspective on clinical translation of these cellular therapies. In summary, evidence from preclinical studies has established stem cells as a potential curative treatment for erectile dysfunction and early phase clinical trials are currently performed.
MSC-derived Nanoparticles ameliorate erectile dysfunction by alleviation of corpus cavernosum smooth muscle apoptosis in a rat model of cavernous nerve injury
MSC-derived Nanoparticles ameliorate erectile dysfunction by alleviation of corpus cavernosum smooth muscle apoptosis in a rat model of cavernous nerve injury.
9:00am - 7:00pm
10:00am - 6:00pm
9:00am - 7:00pm
9:00am - 5:00pm
9:00am - 5:00pm